Product nameAnti-Huntingtin antibody
See all Huntingtin primary antibodies
DescriptionRabbit polyclonal to Huntingtin
Tested applicationsSuitable for: WB, IPmore details
Species reactivityReacts with: Human
Predicted to work with: Horse, Chimpanzee, Cynomolgus monkey, Rhesus monkey, Gorilla, Orangutan
Synthetic peptide within Human Huntingtin aa 1150-1200. The exact sequence is proprietary. (NP_002102.4).
Database link: P42858
- WB: HeLa and HEK-293T whole cell lysate. IP: HeLa whole cell lysate.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
Storage bufferPreservative: 0.09% Sodium azide
Constituents: 0.1% BSA, Tris buffered saline
Concentration information loading...
PurityImmunogen affinity purified
Our Abpromise guarantee covers the use of ab225711 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/2000 - 1/10000. Predicted molecular weight: 348 kDa.|
|IP||Use at 2-5 µg/mg of lysate.|
FunctionMay play a role in microtubule-mediated transport or vesicle function.
Tissue specificityExpressed in the brain cortex (at protein level). Widely expressed with the highest level of expression in the brain (nerve fibers, varicosities, and nerve endings). In the brain, the regions where it can be mainly found are the cerebellar cortex, the neocortex, the striatum, and the hippocampal formation.
Involvement in diseaseDefects in HTT are the cause of Huntington disease (HD) [MIM:143100]. HD is an autosomal dominant neurodegenerative disorder characterized by involuntary movements (chorea), general motor impairment, psychiatric disorders and dementia. Onset of the disease occurs usually in the third or fourth decade of life and symptoms progressively worsen leading to death in 10 to 20 years. Onset and clinical course depend on the degree of poly-Gln repeat expansion, longer expansions resulting in earlier onset and more severe clinical manifestations. HD affects 1 in 10,000 individuals of European origin. Neuropathology of Huntington disease displays a distinctive pattern with loss of neurons, especially in the caudate and putamen (striatum).
Sequence similaritiesBelongs to the huntingtin family.
Contains 10 HEAT repeats.
DomainThe N-terminal Gln-rich and Pro-rich domain has great conformational flexibility and is likely to exist in a fluctuating equilibrium of alpha-helical, random coil, and extended conformations.
modificationsCleaved by apopain downstream of the polyglutamine stretch. The resulting N-terminal fragment is cytotoxic and provokes apoptosis.
Forms with expanded polyglutamine expansion are specifically ubiquitinated by SYVN1, which promotes their proteasomal degradation.
Cellular localizationCytoplasm. Nucleus. The mutant Huntingtin protein colocalizes with AKAP8L in the nuclear matrix of Huntington's disease neurons.
- Information by UniProt
- AI256365 antibody
- C430023I11Rik antibody
- HD antibody
All lanes : Anti-Huntingtin antibody (ab225711) at 0.04 mg/ml
Lane 1 : HeLa (human epithelial cell line from cervix adenocarcinoma) whole cell lysate at 50 µg
Lane 2 : HeLa whole cell lysate at 15 µg
Lane 3 : HeLa whole cell lysate at 5 µg
Lane 4 : HEK-293T (Human epithelial cell line from embryonic kidney transformed with large T antigen) whole cell lysate at 50 µg
Developed using the ECL technique.
Predicted band size: 348 kDa
Exposure time: 10 seconds
Huntingtin was immunoprecipitated from HeLa (human epithelial cell line from cervix adenocarcinoma) whole cell lysate (1 mg for IP, 20% of IP loaded) with ab225711 at 3 µg/mg lysate. Western blot was performed from the immunoprecipitate using ab225711 at 0.4 µg/ml.
Lane 1: ab225711 IP in HeLa whole cell lysate.
Lane 2: Control IgG IP in HeLa whole cell lysate.
Detection: Chemiluminescence with exposure time of 3 seconds.
ab225711 has not yet been referenced specifically in any publications.